{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:41:39Z","timestamp":1771296099089,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1124\/dmd.119.087635","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T23:44:08Z","timestamp":1559778248000},"page":"890-898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways"],"prefix":"10.1016","volume":"47","author":[{"given":"Maciej J.","family":"Zamek-Gliszczynski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuexiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennypher","family":"Mudunuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yewei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal S.","family":"Taskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth H.","family":"Romach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.119.087635_bib1","unstructured":"Alimta (pemetrexed). (2019) Prescribing Information. Eli Lilly and Company, Indianapolis, IN."},{"key":"10.1124\/dmd.119.087635_bib2","unstructured":"Biktarvy (bictegravir\/emtricitabine\/tenofovir alafenamide). (2018) Prescribing Information. Gilead Sciences, Inc., Foster City, CA."},{"key":"10.1124\/dmd.119.087635_bib3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJM199911113412006","article-title":"Neural-tube defects","volume":"341","author":"Botto","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.119.087635_bib4","doi-asserted-by":"crossref","unstructured":"Cabrera RM, Souder JP, Steele JW, Yeo L, Tukeman G, Gorelick DA, Finnell RH (2019) The antagonism of folate receptor by the integrase inhibitor dolutegravir Available from: https:\/\/doi.org\/10.1101\/576272.","DOI":"10.1101\/576272"},{"key":"10.1124\/dmd.119.087635_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/bdra.20318","article-title":"Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect","volume":"79","author":"Candito","year":"2007","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1124\/dmd.119.087635_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","article-title":"Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications","volume":"6","author":"Chattopadhyay","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.119.087635_bib7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00280-017-3304-y","article-title":"Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue","volume":"79","author":"Cohen","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.119.087635_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/seiz.1999.0283","article-title":"Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate","volume":"8","author":"Craig","year":"1999","journal-title":"Seizure"},{"key":"10.1124\/dmd.119.087635_bib9","doi-asserted-by":"crossref","first-page":"g4554","DOI":"10.1136\/bmj.g4554","article-title":"Population red blood cell folate concentrations for prevention of neural tube defects: Bayesian model","volume":"349","author":"Crider","year":"2014","journal-title":"BMJ"},{"key":"10.1124\/dmd.119.087635_bib10","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1001\/jama.1995.03530210052030","article-title":"Folate levels and neural tube defects: implications for prevention","volume":"274","author":"Daly","year":"1995","journal-title":"JAMA"},{"key":"10.1124\/dmd.119.087635_bib11","unstructured":"Depakene (valproic acid). (2011) Prescribing Information. Abbott Laboratories. Chicago, IL."},{"key":"10.1124\/dmd.119.087635_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/tera.1420430304","article-title":"Amelioration by leucovorin of methotrexate developmental toxicity in rabbits","volume":"43","author":"DeSesso","year":"1991","journal-title":"Teratology"},{"key":"10.1124\/dmd.119.087635_bib13","unstructured":"Food and Drug Administration (FDA) (2017) In vitro metabolism- and transporter- mediated drug-drug interaction studies (pharmacology CED, Denver CO) Office of Communications, FDA CDER, Rockville, MD."},{"key":"10.1124\/dmd.119.087635_bib14","doi-asserted-by":"crossref","unstructured":"Ford SL, Lou Y, Lewis N, Kostapanos M, D\u2019Amico R, Spreen W, Patel P (2019) Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects. Antivir Ther DOI: 10.3851\/IMP3306 [published ahead of print].","DOI":"10.3851\/IMP3306"},{"key":"10.1124\/dmd.119.087635_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.119.087635_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/dmd.116.073338","article-title":"Interaction of 2,4-diaminopyrimidine-containing drugs including fedratinib and trimethoprim with thiamine transporters","volume":"45","author":"Giacomini","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087635_bib17","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/13543784.2017.1378643","article-title":"Investigational HIV integrase inhibitors in phase I and phase II clinical trials","volume":"26","author":"Han","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/dmd.119.087635_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/tera.1420520506","article-title":"Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo","volume":"52","author":"Hansen","year":"1995","journal-title":"Teratology"},{"key":"10.1124\/dmd.119.087635_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2013.74","article-title":"Emerging transporters of clinical importance: an update from the International Transporter Consortium","volume":"94","author":"Hillgren","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087635_bib20","unstructured":"Isentress (raltegravir) (2019) Prescribing Information. Merck Sharp & Dohme Corp, Kenilworth, NJ."},{"key":"10.1124\/dmd.119.087635_bib21","unstructured":"Jylamvo (methotrexate) (2017) EPAR: Summary for the public. European Medicines Agency, Amsterdam."},{"key":"10.1124\/dmd.119.087635_bib22","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/bdr2.1366","article-title":"A 2017 global update on folic acid-preventable spina bifida and anencephaly","volume":"110","author":"Kancherla","year":"2018","journal-title":"Birth Defects Res"},{"key":"10.1124\/dmd.119.087635_bib23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cpdd.347","article-title":"A comparative pharmacokinetic study of 2 pemetrexed formulations in Indian adult chemonaive patients with adenocarcinoma stage III\/IV non-small cell lung cancer","volume":"6","author":"Kavathiya","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.119.087635_bib24","first-page":"362","article-title":"Sorting of the human folate receptor in MDCK cells","volume":"37","author":"Kim","year":"2004","journal-title":"J Biochem Mol Biol"},{"key":"10.1124\/dmd.119.087635_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00441-005-1092-x","article-title":"Rat reduced-folate carrier-1 is localized basolaterally in MDCK kidney epithelial cells and contributes to the secretory transport of methotrexate and fluoresceinated methotrexate","volume":"320","author":"Kneuer","year":"2005","journal-title":"Cell Tissue Res"},{"key":"10.1124\/dmd.119.087635_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10555-007-9046-2","article-title":"Human reduced folate carrier: translation of basic biology to cancer etiology and therapy","volume":"26","author":"Matherly","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"10.1124\/dmd.119.087635_bib27","series-title":"Chemisty and Biology of Pteridines and Folates","author":"Milstein","year":"2001"},{"key":"10.1124\/dmd.119.087635_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00498254.2014.942409","article-title":"The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys","volume":"45","author":"Moss","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.119.087635_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.107.122606","article-title":"Functional characterization of human proton-coupled folate transporter\/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter","volume":"322","author":"Nakai","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.087635_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2125.1993.tb04158.x","article-title":"The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis","volume":"35","author":"Seideman","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087635_bib31","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.119.087635_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.placenta.2009.11.017","article-title":"Expression of folate transporters in human placenta and implications for homocysteine metabolism","volume":"31","author":"Solanky","year":"2010","journal-title":"Placenta"},{"key":"10.1124\/dmd.119.087635_bib33","unstructured":"Stribild (elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate). (2019) Prescribing Information. Gilead Sciences, Inc., Foster City, CA"},{"key":"10.1124\/dmd.119.087635_bib34","unstructured":"Tivicay (dolutegravir). (2018) Prescribing Information. ViiV Healthcare, Research Triangle, NC."},{"key":"10.1124\/dmd.119.087635_bib35","unstructured":"Vitekta (elvitegravir). (2015) Prescribing Information. Gilead Sciences, Inc., Foster City, CA."},{"key":"10.1124\/dmd.119.087635_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.108.023648","article-title":"Relationship between drug\/metabolite exposure and impairment of excretory transport function","volume":"37","author":"Zamek-Gliszczynski","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087635_bib37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2013.45","article-title":"ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans","volume":"94","author":"Zamek-Gliszczynski","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087635_bib38","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cpt.1112","article-title":"Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance","volume":"104","author":"Zamek-Gliszczynski","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087635_bib39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.119.087635_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-nutr-072610-145133","article-title":"Mechanisms of membrane transport of folates into cells and across epithelia","volume":"31","author":"Zhao","year":"2011","journal-title":"Annu Rev Nutr"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.119.087635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:50:01Z","timestamp":1740055801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0090955624079583"],"URL":"https:\/\/doi.org\/10.1124\/dmd.119.087635","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.119.087635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}